

ALG10B Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP5630b

Specification

ALG10B Antibody (C-term) Blocking peptide - Product Information

Primary Accession
Other Accession

[Q5I7T1](#)
[NP_001013642.1](#)

ALG10B Antibody (C-term) Blocking peptide - Additional Information

Gene ID 144245

Other Names

Putative Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1, 2-glucosyltransferase, Alpha-1, 2-glucosyltransferase ALG10-A, Alpha-2-glucosyltransferase ALG10-B, Asparagine-linked glycosylation protein 10 homolog B, Potassium channel regulator 1, ALG10B, KCR1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ALG10B Antibody (C-term) Blocking peptide - Protein Information

Name ALG10B ([HGNC:31088](#))

Function

Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2- glucosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses. Once assembled, the oligosaccharide is transferred from the lipid to nascent proteins by oligosaccharyltransferases. In the lumen of the endoplasmic reticulum, adds the third and last glucose residue from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide intermediate Glc(2)Man(9)GlcNAc(2)-PP-Dol to produce Glc(3)Man(9)GlcNAc(2)-PP-Dol.

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein. Note=Also detected at the plasma membrane {ECO:0000250|UniProtKB:O88788}

Tissue Location

Highly expressed in heart, placenta, liver, kidney and pancreas. Weakly expressed in lung, skeletal muscle and brain

ALG10B Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

ALG10B Antibody (C-term) Blocking peptide - Images**ALG10B Antibody (C-term) Blocking peptide - Background**

Putative alpha-1,2-glucosyltransferase, which adds the third glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Glc(2)Man(9)GlcNAc(2)-PP-Dol. When coupled to KCNH2 may reduce KCNH2 sensitivity to classic proarrhythmic drug blockade, possibly by mediating glycosylation of KCNH2.

ALG10B Antibody (C-term) Blocking peptide - References

Daly, A.K., et al. Nat. Genet. 41(7):816-819(2009)Petersen, C.I., et al. Proc. Natl. Acad. Sci. U.S.A. 101(32):11773-11778(2004)Kupershmidt, S., et al. FASEB J. 17(15):2263-2265(2003)